J&J’s Ethicon Earns EU Approval for Ethizia Hemostatic Sealing Patch

Johnson & Johnson MedTech company Ethicon has gained CE mark approval for Ethizia, and adjunctive hemostatic sealing patch for difficult-to-control bleeding situations.
 
Composed of Ethicon’s polyoxazoline-based synthetic polymer material, the company claimed Ethizia is the first, only hemostatic matrix engineered to be equally active and effective on both sides. The patch can be stuffed, rolled, pulled apart, trimmed, and tailored as well, Ethicon said, to it can be handled in either open or minimally invasive surgeries.
 
The company also said in 80% of clinical trial patients studied, Ethizia stopped bleeding in 30 seconds.
 
Ethizia is specifically indicated as an adjunctive hemostat for disruptive bleeding on internal organs that aren’t cardiovascular or neurological. Ethicon aims to launch it in its EMEA territory in Q1 2024, with other key markets following regulatory approvals.
 
“As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions,” Ethicon’s company group chairman Vladimir Makatsari told the press. “Disruptive bleeding can contribute to serious complications, and with the addition of ETHIZIA to our portfolio, we are well positioned to deliver critical hemostasis solutions for patients.”
 
The hemostatic patch was acquired in May 2022 with Ethicon’s purchase of Netherlands-based GATT Technologies.